Just reported
Q3 2026 results
From Harmony Biosciences Holdings, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Revenue
Actual
$268.9M
+12% y/y ↑
+2.9% q/q ↑
EPS, GAAP
Actual
$0.81
-6.9% y/y ↓
-37% q/q ↓
Operating income, GAAP
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|
| Total Revenue | $268.9M | $239.5M | +12.30% |
| Profit | $48.2M | $50.9M | -5.25% |
| Profit per share | $0.81 | $0.87 | -6.90% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
NewThe latest call
FetchingHarmony Biosciences Holdings, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
What management said
“As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate si gnificant long-term value,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Close before
$37.02
Nov 3, 2026
Close after
$32.47
Nov 5, 2026
Move
-12.29%
2.47M shares traded, against a normal 1.01M
What Harmony Biosciences Holdings, Inc. does
Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Harmony Biosciences Holdings, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
